August 10, 2026

EyePoint Completes Enrollment in Phase 3 DME Trials

More than 480 patients have joined the COMO and CAPRI studies evaluating six-month dosing of EyePoint’s investigational retinal therapy, DURAVYU

The Ophthalmologist

August 06, 2026

Sharper Targets for Retinal Repair

Researchers map distinct photoreceptor precursor states that could help refine future cell therapies for retinal degeneration

The Ophthalmologist

August 03, 2026

Enzyme Disruption Could Impair Retinal Homeostasis

Preclinical models showed that impaired endolysosomal trafficking preceded photoreceptor degeneration and disrupted retinal pigment epithelial cell function.

MDSpire News

July 24, 2026

FDA Approves Ophthalmic Bevacizumab

The approval establishes the first and only FDA-approved ophthalmic formulation of bevacizumab for neovascular age-related macular degeneration in the US.

MDSpire News

July 22, 2026

Looking Deeper With STOC-T

New review explores how spatio-temporal optical coherence tomography preserves useful photons and suppresses scattered light

The Ophthalmologist

July 20, 2026

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

MDSpire News

July 15, 2026

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

Retinal Physician

July 15, 2026

ASRS President Reflects on a Year of Change

As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.

Retinal Physician

July 13, 2026

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

MDSpire News

July 01, 2026

Connecting Structure and Function in GA

Post hoc GATHER2 analyses presented at ASRS 2026 suggest ellipsoid zone integrity and low-luminance deficit may provide complementary measures of disease progression and treatment response.

Retinal Physician